AIVIS, a Seoul AI Hub–affiliated company supported by the Seoul Metropolitan Government, announced on December 23 that it was selected as a winner of the Ministry of SMEs and Startups’ (MSS) “2025 Excellent SME Product” program, earning the President’s Award from The Korea Economic Daily. The program recognizes outstanding SME products each year based on technological excellence, market potential, and innovation. Winners are selected through expert review and on-site evaluations led by MSS across sectors including healthcare, manufacturing, and services. AIVIS was recognized for Qanti® IHC, an AI-based immunohistochemistry (IHC) analysis solution. The software quantitatively analyzes the expression of key biomarkers in cancer tissue—such as HER2, ER, PR, and Ki-67—to improve the accuracy and efficiency of pathological diagnosis. It was selected for its precise and consistent quantification capabilities and its demonstrated clinical applicability. According to AIVIS, Qanti® IHC received approval from the Ministry of Food and Drug Safety as an in vitro diagnostic medical device in September last year. The company added that the solution is currently supplied to 12 top-tier tertiary hospitals in Korea and is being used in cancer diagnosis and treatment decision-making. By providing objective quantitative values—even across more finely stratified biomarker expression ranges—the software is designed to help reduce subjective variation that can arise during manual interpretation by pathologists. AIVIS also said it is conducting digital pathology solution deployments and proof-of-concept (PoC) projects with more than 20 hospitals overseas, including across Asia, as it works to help advance standardization of cancer tissue analysis and biomarker quantification. “Receiving official recognition is meaningful in that our digital pathology technology has been acknowledged for its ability to support accurate cancer diagnosis and treatment decisions,” said Daehong Lee, CEO of AIVIS. “Based on interoperability verification with global pathology companies such as Philips and Roche, we plan to expand the digital pathology ecosystem and accelerate our entry into key overseas markets.”